Gilead Sciences Inc.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
15.70%
Market Cap
136.55 Bil.
P/E Ratio
18.10
Dividend Yield
2.57 %
Earnings per Share
6.01 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 109.98 G | 0 Units |
| PRICE DETERMINATION TIME | 06/23/2026 / 09:57:25 PM | |
| DAILY VOLUME (UNITS) | 69 | |
| DAILY HIGH / LOW | 111.02 | 108.64 |
| PREV. DAY'S PRICE | 109.28 | (06/22) |
| CHANGE DAY BEFORE | +0.70 | 0.64 % |
| 52 WEEK HIGH / LOW | 132.16 (02/11) | 90.03 (06/26) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 8.43 | -0.66 | 6.01 | 0.35 | 4.17 |
| DIVIDENDS PER SHARE | 2.90 | 2.86 | 2.80 | 2.85 | 2.77 |
| DIVIDEND YIELD IN % | - | - | 2.57 % | 3.33 % | 3.70 % |
| DIVIDEND GROWTH IN % | - | - | -1.63 % | 2.61 % | -0.07 % |
| PRICE - EARNINGS RATIO | 12.80 | - | 18.10 | 241.49 | 17.99 |
| PRICE - BOOK RATIO | - | - | 6.71 | 5.95 | 4.42 |
| PRICE - SALES RATIO | - | - | 5.23 | 4.04 | 3.77 |
| PRICE - CASH FLOW RATIO | - | - | 15.37 | 10.71 | 12.73 |
Master Data
| WKN | 885823 |
| ISIN | US3755581036 |
| SYMBOL | GIS |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Gilead Sciences |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 1.24 Bil. |
| MARKET CAPITALISATION | 136.55 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.05 % | -5.65 % | -7.78 % | 3.68 % | 15.70 % | 53.44 % | 93.72 % | 3.31 % |
| HIGH | 110.14 | 117.88 | 122.00 | 132.16 | 132.16 | 132.16 | 132.16 | 132.16 |
| LOW | 106.02 | 105.04 | 105.04 | 99.98 | 90.03 | 57.32 | 52.29 | 99.98 |
Dividend
per share
Company profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Structured products for Gilead Sciences Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.